VOR - Vor Biopharma Inc.
Chart Events
Slow Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 4.6900 |
| Open | 4.7600 |
| Bid | 4.5000 x 1000 |
| Ask | 4.7900 x 1800 |
| Day's Range | 4.6000 - 4.7900 |
| 52 Week Range | 3.4800 - 7.5700 |
| Volume | |
| Avg. Volume | 126,008 |
| Market Cap | 320.723M |
| Beta (5Y Monthly) | -0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2000 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.17 |
Fair Value
Related Research
GlobeNewswireVor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
VBP101 clinical data update planned at European Hematology Association (EHA) 2023VCAR33ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2023, and provided a business update. “We are pleased with the progress we made during the quarter. Our focus continues to be on actively enrolling and treating additio
Simply Wall St.We Think Vor Biopharma (NASDAQ:VOR) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual SummitFireside Chat: Monday, April 24, 2023 at 9:30 am ET H.C. Wainwright BioConnect Investor Conference Fireside Chat: Tuesday, May 2, 2023 at 12:00 pm ETLocation: Nasdaq World Headquarters, New York, NY
ZacksHow Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- GlobeNewswire
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplantAdditional trem-cel data expected by year-end 2023; VCAR33ALLO on track for IND submission in first half of 2023$116M financing extends expected cash runway into Q1 2025 CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and
- Simply Wall St.
Vor Biopharma Inc. (NASDAQ:VOR) Shares Could Be 43% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Vor Biopharma is US$9.25 based on 2 Stage Free Cash Flow to Equity Vor...
BenzingaVor Biopharma's Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant
Vor Biopharma Inc (NASDAQ: VOR) presented clinical data from VBP101, its Phase 1/2a study of trem-cel (previously VOR33) in patients with acute myeloid leukemia (AML). In the first patient, trem-cel maintained hematopoiesis through three cycles of Mylotarg (gemtuzumab ozogamicin), which was well-tolerated at the initial dose of 0.5 mg/m2. Patient 1 maintained neutrophil and platelet counts approximately five months (147 days) after transplantation with trem-cel. Due to detectable, measurable res
- GlobeNewswire
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of MylotargMylotarg treatment enriched CD33-negative donor hematopoiesisSecond patient successfully received trem-cel transplant and achieved neutrophil engraftment and platelet recovery CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, presented clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study
- GlobeNewswire
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML) has been accepted as a late-breaking poster presentation at the 2023 Tandem Meetings, the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, tak
- GlobeNewswire
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities’ 3rd Annual Oncology Conference. B. Riley Securities’ 3rd Annual Oncology Conference – Fireside ChatDate: Wednesday, January 18, 2023Time: 12:00 PM ET A live webcast of the presentation will be available via the Investors section of the Company's website at www.vorbio.com. An archived repla
- GlobeNewswire
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million. In the underwritten offering, Vor Bio has agreed to sell 15,302,267 shares of its common stock at an offering price of $4.30 per share. Before deducting the underwriting discounts and commissions and offering expenses, the compa
- GlobeNewswire
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
Trem-cel (formerly VOR33) successfully manufactured and engrafted normallyBlood counts successfully maintained following post-transplant treatment with MylotargConference call scheduled for today, December 7 at 8:00am ET CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of tremtelectogene empogeditemcel or “
TipRanks2 “Strong Buy” Penny Stocks That Could Rally All the Way to $15
Which stocks are either a fan favorite or a must-avoid? Penny stocks. These tickers going for less than $5 apiece are particularly divisive on Wall Street, with those in favor as well as the naysayers laying out strong arguments. These names are too appealing for the risk-tolerant investor to ignore. Given the low prices, you get more for your money. On top of this, even minor share price appreciation can translate to massive percentage gains, and thus, major returns for investors. However, ther
- GlobeNewswire
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
Initial clinical data for VOR33 on track for Q4 2022Eyal C. Attar, M.D. appointed as Chief Medical OfficerInitiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2022 and provided a business update. “We continue to actively enroll patients in our lead clinical trial, VBP101
- Simply Wall St.
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO). Dr. Attar brings more than 20 years of demonstrated clinical experience to the position, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. “This is a time of tremendous momentum for Vor Bio with initial data
- GlobeNewswire
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European Society of Gene & Cell Therapy (ESGCT) Annual Congress CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced data demonstrating the potential of the Company’s novel platform to use various base editing strategies
- GlobeNewswire
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
Facility to support clinical manufacturing for Vor Bio’s novel cell and genome engineering pipeline while reducing the time and cost required to manufacture its eHSC and CAR-T product candidatesCAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the opening of its new in-house clinical manufacturing facility in Cambridge, Mass. co-located in the Company’s current headquarters. The new facility is design
ZacksCan Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 298.3% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksHow Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295%
The consensus price target hints at a 295% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GlobeNewswireVor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update
Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022In-house manufacturing facility in Cambridge, MA operational in Q4 2022Data presented at EHA successfully demonstrates in-vivo engraftment of multiplex edited HSCs for next-generation AML treatmentCash runway extended into Q1 2024 CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial result
- GlobeNewswire
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited hematopoietic stem and progenitor cells persisted long-term post engraftment, with minimum translocation risk CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced successful first of its kind dual editing of CD